The effects through which methotrexate reduces CV event rates in RA patients are several and still not fully understood; it is however known that the clinical response to treatment is associated with reduction of inflammation and reduction in the expression of inflammatory cytokines such as TNF-alpha and IL-6, which, as aforementioned, have proatherogenic effects. The gene discussed is IL6; the disease is rheumatoid arthritis.